According to Marketbeat, the 19 research firms currently tracking Accolade, Inc. (NASDAQ: ACCD-Get Rating) have given the stock a recommendation of “Moderate Buy” as the consensus rating the stock. Marketbeat notes that this recommendation was provided. Nine different financial analysts have recommended the firm with a buy recommendation, while seven have provided the company with a hold rating. The brokerage firms that changed their coverage during the previous year have set an average price target of $17.71 for the next year’s worth of trading for the underlying security.
Recently, the company has been given feedback from several research experts. This information has been received. In a research note published on Thursday, Piper Sandler maintained its “overweight” rating on shares of Accolade and set a target price of $12.00 for the company’s stock. Goldman Sachs Group gave accolade a “buy” rating in a research report published on Friday, July 1. At the same time, the firm lowered its price objective for the stock from $15.00 to $13.00. The report’s subject matter was the corporation. On Friday, August 12, DA Davidson’s study report, initially published the previous Friday, referred Accolade for the first time. They recommended that the company “buy” the stock and established a price goal of $16.00 for the stock.
In a report that Truist Financial disseminated on Wednesday, the very first time that the name Accolade was mentioned was in the document. They suggested investing in the company’s stock and establishing a price target of $15 per share. In a research note made public on Friday, July 1, Berenberg Bank maintained a “buy” rating on shares of Accolade and set a price objective of $11.00 on the company’s stock. On Friday, the opening price for trading ACCD shares was $11.44, which remained unchanged throughout the day. All three of these ratios, the current ratio, the quick ratio, and the current debt-to-equity ratio, are all 3.95, yet the debt-to-equity ratio is only 0.53. The all-time high for Accolade during this period was $48.35, while the all-time low was $4.61. The company’s value can be broken down into its market valuation, which is currently sitting at $814.63 million; its PE ratio, which is currently sitting at 1.88; and its beta, which is currently sitting at 2.10
. The price of a share of the company’s stock is now trading at an average of fifty days of $10.50, and the price that moves forward two hundred days is $10.81. On June 30, the most recent quarterly report for Accolade (NASDAQ: ACCD-Get Rating) was made available for the general public to review. The firm reported earnings per share (EPS) for the quarter at $0.62, which was $0.33 more than the average forecast of $0.95. The sales made by the company during the period were $85.53 million, which is significantly higher than the consensus prediction of $81.97 million, which market analysts made. Accolade had a negative return on equity of 23.63% and a negative net margin of 124.17% in its financial statements. The company’s quarterly sales climbed by 43.7% when measured against the results achieved during the same quarter in the preceding year. The previous year at this time, the company experienced a loss in sales equivalent to $0.52 per share.
This loss occurred throughout the same period. Sell-side analysts project that Accolade will have earnings of -6.53 cents per share in 2018, resulting in a loss for the company. In other news relating to this topic, Rajeev Singh, Chief Executive Officer of Accolade, purchased 17,500 shares of the company’s stock on Tuesday, August 2. The total price of the shares was $176,575.00, which comes out to an average price of $10.09 per share. This brings the total price of the shares to $176,575.00. Following the successful conclusion of the transaction, the Chief Executive Officer was vested with direct ownership of 149,697 shares of the company, each of which has a current market value of $1,510,442.73. On the Securities and Exchange Commission (SEC) website, one can acquire access to the filing in which the transaction was disclosed. Insiders of the company sold 7,808 shares of company stock during the preceding quarter for a total price of $50,302, bringing in the proceeds.
Company insiders hold the total number of shares in the corporation at a rate of 7.30 percent. Recently, several institutional investors and hedge funds have either boosted the amount of ACCD they are now holding in their portfolios or decreased the amount they are holding in their portfolios. A subsidiary of the Swiss National Bank known as Zurich Cantonalbank increased the number of Accolade shares it owned by 48.1% during the first three months of 2018. Swiss National Bank (Zürich Kantonalbank): Following the purchase of 2,103 additional shares during the most recent quarter, Zurich Cantonalbank now directly owns 6,473 shares of the company’s stock, which has a value of $114,000.00. This brings the total number of shares directly owned by the company to 6,473. During the second quarter of the fiscal year, Parallel Advisors LLC increased the percentage of Accolade shares it owned by 171.5%. After making an additional purchase of 5,505 shares during the most recent quarter of the company’s fiscal year, Parallel Advisors LLC now has a total of 8,714 shares of the company’s stock. These shares are currently fetching the market price is $64,000. Caption Management LLC increased the size of its assets in Accolade by 217.5 percent during the second quarter.
Following the acquisition of an additional 18,500 shares during the most recent quarter, Caption Management LLC now holds 10,000 shares of the company’s stock. Each share of the company’s stock is now worth $74,000, giving the company a total market value of $74,000. Quantamental Technologies LLC shelled out about $178,000 over the first three months of 2018 to acquire further shares of Accolade. Last but not least, First Republic Investment Management Inc. provided Accolade with a new investment of approximately $75,000 worth of shares to be distributed across the company’s stock during the second quarter. Institutional investors and hedge funds collectively own 78.33% of the total number of shares in the company, making up the majority of the company’s shareholders. Accolade, Inc. and its subsidiaries develop and supply technology-enabled solutions that aid Americans in grasping, utilizing, and navigating their job benefits as well as the healthcare system. These solutions are developed and delivered by Accolade, Inc.
The company not only offers a platform that is stored in the cloud but also offers multimodal assistance from a staff of health professionals. Some examples of these professionals are nurses, medical directors, and people specializing in mental health.